ストックスクリーナーアプリを入手
7.81
2.01%
-0.16
前日終値:
$7.97
開ける：
$7.91
24時間の取引高:
1.16M
Relative Volume:
1.62
時価総額：
$298.89M
収益：
$127.70M
当期純損益:
$-121.25M
株価収益率:
-2.4794
EPS:
-3.15
ネットキャッシュフロー:
$-120.32M
1週間 パフォーマンス:
+17.18%
1か月 パフォーマンス:
+25.56%
6か月 パフォーマンス:
-5.10%
1年 パフォーマンス:
-56.37%
1日の値動き範囲:
$7.73
$8.04
1週間の範囲:
$6.74
$8.50
52週間の値動き範囲:
$4.80
$18.70
Iteos Therapeutics Inc Stock (ITOS) Company Profile
ITOS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
7.81 | 255.09M | 127.70M | -121.25M | -120.32M | -3.15 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-05-14 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-08-13 | 開始されました | Wells Fargo | Overweight |
| 2021-05-05 | 開始されました | H.C. Wainwright | Buy |
| 2020-10-08 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | SVB Leerink | Outperform |
| 2020-08-18 | 開始されました | Wedbush | Outperform |
すべてを表示
Iteos Therapeutics Inc (ITOS) 最新ニュース
Research Analysts Issue Forecasts for ITOS Q2 Earnings - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Target Price from Analysts - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Reiterates “Market Perform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
ITOS: ITeos Therapeutics Downgraded to Neutral by HC Wainwright & Co. | ITOS Stock News - GuruFocus
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating (NASDAQ:ITOS) - Seeking Alpha
Piper Sandler cuts iTeos stock price target to $12 from $16 - Investing.com Canada
ITeos Therapeutics (ITOS) Sees Price Target Adjustment by Piper Sandler | ITOS Stock News - GuruFocus
ITeos Therapeutics (ITOS): Analyst Lowers Price Target, Rating R - GuruFocus
Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth - TipRanks
ITeos Therapeutics (ITOS) Downgraded by Leerink Partners | ITOS Stock News - GuruFocus
This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday - Benzinga
Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform - marketscreener.com
iTeos Therapeutics (ITOS) Receives Adjusted Price Target from We - GuruFocus
iTeos Therapeutics (ITOS) Faces Downgrade Following GSK's Decisi - GuruFocus
GSK (GSK) and iTeos Halt Belrestotug Development After Disappoin - GuruFocus
iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler - TipRanks
iTeos Therapeutics (ITOS) Downgraded by Analyst with New Price T - GuruFocus
Leerink downgrades iTeos Therapeutics after termination of TIGIT program - TipRanks
iTeos and GSK halt lung cancer drug development By Investing.com - Investing.com India
GSK, partner iTeos end development programme for lung cancer drug belrestotug - Medical Dialogues
ITeos Therapeutics (ITOS) Downgraded by JP Morgan | ITOS Stock N - GuruFocus
As iTeos, GSK shelve belrestotug, prospects for TIGIT continue to dim - BioCentury
iTeos Therapeutics: TIGIT Falls, And A Zombie Rises? (NASDAQ:ITOS) - Seeking Alpha
iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop - insights.citeline.com
JPMorgan cuts iTeos Therapeutics stock rating to neutral, target to $8 - Investing.com Australia
GSK and iTeos end belrestotug antibody program By Investing.com - Investing.com Nigeria
iTeos Therapeutics (ITOS) Downgraded by JPMorgan Analyst | ITOS Stock News - GuruFocus
GSK, partner iTeos scrap development of lung cancer therapy - NewsBreak: Local News & Alerts
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile - Benzinga
iTeos and GSK to drop belrestotug + dostarlimab collaboration - The Pharma Letter
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Stu - GuruFocus
iTeos, GSK to shelve TIGIT drug after study setback - BioPharma Dive
ITeos Terminates TIGIT Program After Phase 2 Lung Study Misses PFS Endpoint, Explores Options - Nasdaq
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish - Asianet Newsable
ITeos, GSK discontinue lung cancer therapy development - KFGO
Wedbush Adjusts Price Target on iTeos Therapeutics to $10 From $25, Maintains Outperform Rating - marketscreener.com
GSK (GSK) and iTeos Halt Development of Lung Cancer Drug Combo - GuruFocus
GSK, iTeos Therapeutics End Belrestotug Development Program - marketscreener.com
iTeos stock rises despite clinical trial setback By Investing.com - Investing.com South Africa
iTeos stock rises despite clinical trial setback - Investing.com Australia
iTeos (ITOS) Takes Strategic Steps After Disappointing Study Res - GuruFocus
GSK Ends Small-Molecule Drug Belrestotug Development Program - marketscreener.com
GSK, iTeos End Development of Experimental Lung Cancer Drug - Bloomberg
GSK, iTeos end lung cancer asset development after trial failure - Seeking Alpha
iTeos and GSK halt lung cancer drug development - Investing.com Australia
GSK and iTeos end belrestotug antibody program - Investing.com
GSK provides update on belrestotug development programme - GSK
iTeos Reports Topline Interim Results from GALAXIES - GlobeNewswire
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - Stock Titan
Dimensional Fund Advisors LP Has $9.29 Million Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc (ITOS) 財務データ
収益
当期純利益
現金流量
EPS
Iteos Therapeutics Inc (ITOS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 14 '25 |
Buy |
7.41 |
1,658,978 |
12,285,562 |
7,388,978 |
| GADICKE ANSBERT | Former 10% Owner |
May 13 '25 |
Sale |
8.06 |
1,031,931 |
8,317,364 |
3,452,797 |
| MPM BIOVENTURES 2018, L.P. | Former 10% Owner |
May 13 '25 |
Sale |
8.06 |
630,191 |
5,079,339 |
2,108,594 |
| MPM BioVentures 2014, L.P. | Former 10% Owner |
May 13 '25 |
Sale |
8.06 |
630,191 |
5,079,339 |
2,108,594 |
| Van Hauwermeiren Timothy | Director |
May 13 '25 |
Option Exercise |
4.30 |
22,346 |
96,088 |
22,346 |
| Gall Matthew | Chief Financial Officer |
Nov 19 '24 |
Buy |
7.73 |
5,000 |
38,635 |
65,429 |
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):